On August 6, the stock of Cohance Lifesciences opened lower, trading at Rs 424.20. This was a drop of Rs 4.75 or 1.11% from the previous close on the Bombay Stock Exchange.
The decline came after the U.S. Food and Drug Administration finished inspecting the company’s Hyderabad plant. The inspection covered the facility in Pashamylaram from July 27 to August 5, 2026.
At the end of the inspection, the FDA issued a Form 483 that listed five observations. The company confirmed that none of these observations relate to data integrity problems.
Cohance said it is reviewing the observations and will file a detailed response with corrective and preventive actions (CAPAs) within the required time frame. It also said the issues are addressable and that it will work closely with the regulator.
In the June quarter, the company’s operating revenue fell 23.1% year‑on‑year to ₹422.26 crore, down from ₹549.31 crore a year earlier. The company posted a loss of ₹24.12 crore, compared to a profit of ₹48.88 crore in the same period last year.
The share closed at Rs 428.95 in the previous session, up Rs 3.75 or 0.88%.
The stock has seen a 52‑week high of Rs 1,038.00 on September 8, 2025, and a low of Rs 267.85 on March 9, 2026. Today, it trades 58.68% below the high and 60.15% above the low.
The company’s market capitalisation stands at Rs 16,411.51 crore.